Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | CHIEF TECH OP OFFICER | May 01, 2025 | May 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUTRO BIOPHARMA, INC.
Report date May 01, 2025 · Filed May 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,686 |
Ending reported balance
After 2025-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-01 · Exercise / conversion · Acquired 2,500 · Balance 54,580 Row 2 · 2025-05-01 · Tax withholding · Disposed 894 · Balance 53,686 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2027-05-01 | Direct | 5,000 |
Reported balance
After 2025-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-01 · Exercise / conversion · Disposed 2,500 · Balance 5,000 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3: The RSUs vest as to 1/4th of the total award annually beginning on May 1, 2024, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The RSUs vest as to 1/4th of the total award annually beginning on May 1, 2024, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 5, 2025 21:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011997 · form4-05052025_090515.xml · derivative · entry 3 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2027-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on May 1, 2024, subject to continued service through each vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 894 | $1.07 | $956.58 |
DisclosureSEC source: 0001415889-25-011997 · form4-05052025_090515.xml · nonDerivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,686 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:46 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011997 · form4-05052025_090515.xml · nonDerivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010683 · form4-04152025_080443.xml · derivative · entry 3 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 21,250 shares Expires 2026-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on April 11, 2023, subject to continued service through each vesting date. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 7,603 | $0.60 | $4,561.80 |
DisclosureSEC source: 0001415889-25-010683 · form4-04152025_080443.xml · nonDerivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,080 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010683 · form4-04152025_080443.xml · nonDerivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:07 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 94,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010382 · form4-04082025_080441.xml · derivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,250 Underlying: Common Stock · 94,250 shares Expires 2029-03-02 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 2, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:07 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy) · Derivative | 101,500 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-25-010382 · form4-04082025_080441.xml · derivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,500 Underlying: Common Stock · 101,500 shares Expires 2035-04-04 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on May 4, 2025, with 100% of the award being vested and exercisable on April 4, 2029, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006656 · form4-03042025_100339.xml · derivative · entry 5 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,125 Underlying: Common Stock · 6,375 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006656 · form4-03042025_100339.xml · derivative · entry 4 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 4,672 | $1.59 | $7,428.48 |
DisclosureSEC source: 0001415889-25-006656 · form4-03042025_100339.xml · nonDerivative · entry 3 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,433 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006656 · form4-03042025_100339.xml · nonDerivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:58 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006656 · form4-03042025_100339.xml · nonDerivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012170 · form4-05032024_080512.xml · derivative · entry 3 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2027-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on May 1, 2024, subject to continued service through each vesting date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 892 | $3.74 | $3,336.08 |
DisclosureSEC source: 0001415889-24-012170 · form4-05032024_080512.xml · nonDerivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,730 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012170 · form4-05032024_080512.xml · nonDerivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 21:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010772 · form4-04122024_090423.xml · derivative · entry 3 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 21,250 shares Expires 2026-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on April 11, 2023, subject to continued service through each vesting date. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 21:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 7,582 | $4.50 | $34,119.00 |
DisclosureSEC source: 0001415889-24-010772 · form4-04122024_090423.xml · nonDerivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,122 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 21:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010772 · form4-04122024_090423.xml · nonDerivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007189 · form4-03072024_090338.xml · derivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2028-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 34,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001415889-24-007189 · form4-03072024_090338.xml · derivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006738 · form4-03052024_090304.xml · derivative · entry 3 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,049 | $4.95 | $10,142.55 |
DisclosureSEC source: 0001415889-24-006738 · form4-03052024_090304.xml · nonDerivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,454 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006738 · form4-03052024_090304.xml · nonDerivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · CHIEF TECH OP OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026736 · doc4.xml · derivative · entry 2 Srinivasan Venkatesh · CIK 0001974888 · Chief Tech Op Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common · 10,000 shares Expires 2027-05-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on May 1, 2024, subject to continued service through each vesting date. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 7,500 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001209191-23-026736 · doc4.xml · derivative · entry 1 Srinivasan Venkatesh · CIK 0001974888 · Chief Tech Op Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on June 1, 2023, with 100% of the total shares vested and exercisable on May 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.